However, we found that CD73 expression was not different among CD8+ naive T cells, CD8+ Med cells, and CD8+CD103+ iTregs (Figure S2); thus, CD39, but not CD73, identifies the CD8+ iTreg population that displays advantages in suppressing immune responses and responding to cell therapy in lupus nephritis. The gene discussed is NT5E; the disease is lupus nephritis.